Real World COVID-19 Antiviral Effectiveness Research

Launched by CLINICAL RESEARCH CENTRE, MALAYSIA · Dec 4, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of two oral antiviral treatments, nirmatrelvir plus ritonavir and molnupiravir, for people who have tested positive for COVID-19. The goal is to see how well these medications work in real-life situations at health clinics over a period of 90 days. The study is currently looking for participants, and anyone aged 65 or older who has tested positive for COVID-19 and meets the Ministry of Health Malaysia guidelines for treatment may be eligible to join.

If you decide to participate, you will be monitored by health professionals as they track your health and any changes in your COVID-19 symptoms during the study period. It’s important to note that if you have already started taking one of these antiviral medications more than five days after your positive test, you won’t be able to participate. This trial aims to gather valuable information that could help improve COVID-19 treatment for everyone.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All SARS-CoV-2 positive individuals who are eligible for oral antiviral treatment based on current Ministry of Health Malaysia guidelines.
• Exclusion Criteria:
• • Individual who received oral antiviral (either nirmatrelvir plus ritonavir or monupiravir) more than 5 days following their positive SARS-CoV-2 test date

Trial Officials